Take Advantage Of The ‘Summer Dip’ With The FTSE 100, AstraZeneca plc & Vodafone Group plc

Now could be a great time to buy AstraZeneca plc (LON: AZN), Vodafone Group plc (LON: VOD) and the FTSE 100 (INDEXFTSE:UKX).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE100

‘Sell in May and don’t come back until St. Ledger’s day’ is a well-known saying in investing circles. Indeed, data from recent decades seems to back it up: the stock market rarely embarks on a sustained summer rally and usually falls between May and September. This has been the case in 2014, with the FTSE 100 falling by 1% over the last three months.

This means that the index is flat for the year so far, although it still appears to offer good value for money when compared to its American cousin, the S&P 500. While it trades on a price to earnings (P/E) ratio of 18.5, our FTSE 100 has a P/E of just 13.4. So, while many commentators have been getting excited about our ‘summer dip’ in terms of it being the beginning of a prolonged market correction, it could turn out to be little more than a mild, mundane and entirely predictable summer pullback.

Great Value

As a result of falls in the last few months, many top-notch FTSE 100 stocks are now even better value than they were in May. Two fine examples are AstraZeneca (LSE: AZN) and Vodafone (LSE: VOD). The former has fallen by 1.5% during the last three months, while the latter is down 7% over the same time period. This means that both companies now offer above-average yields of 4% and 5.7% respectively, which highlights their attractive valuations at current price levels.

Looking Ahead

However, there is a lot more to AstraZeneca and Vodafone that attractive prices. For example, AstraZeneca continues to make huge improvements to its drug pipeline and is gradually overcoming a sizeable patent cliff that has caused the company’s top and bottom lines to fall in recent years. Similarly, Vodafone is pursuing a sound strategy of buying undervalued assets in Europe. Although it may take many years for this strategy to come good, it looks set to put Vodafone on a long term path to strong growth and stability, which is great news for shareholders.

Certainly, the ‘summer dip’ may not yet be over. The FTSE 100, including AstraZeneca and Vodafone, may fall further. However, they seem to offer top notch value for money at present and appear to have bright futures. Indeed, with the UK economy continuing to pick up pace, and with interest rates looking less likely to move higher as a result of lower than expected inflation, a purple patch could be just around the corner. As a result, it could be worth coming back a little before St. Ledger’s day!

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Here’s what £20,000 invested in IAG shares at the start of 2024 would be worth today

IAG shares smashed the FTSE 100 in 2024, and Harvey Jones is kicking himself for squandering this buying opportunity. But…

Read more »

Investing Articles

BP shares are forecast to return 30% in 2025 – and they’re filthy cheap with a P/E of 5.8!

Harvey Jones bought BP shares twice in the autumn and after a bumpy start he expects great things in the…

Read more »

Investing Articles

At a P/E ratio of 8, are shares in this FTSE 100 winner unbelievable value?

3i is a top-performing UK stock that trades at a P/E multiple of 8. Should value investors be snapping up…

Read more »

Investing Articles

Best British growth stocks to consider buying in 2025

We asked our freelance writers to reveal the top growth stocks they’d buy in 2025, which included two 'Fire' recommendations!

Read more »

Passive income text with pin graph chart on business table
Investing Articles

2 shares to consider for turning an empty ISA into a £31,301 a year passive income machine

Earning passive income doesn’t take huge amounts of cash to start with. Investing in great companies consistently over time can…

Read more »

Investing Articles

What £20,000 invested in BT shares at the start of 2024 is worth now…

BT shares enjoyed a solid 2024, Harvey Jones discovers, especially once the bumper dividend is taken into account. So should…

Read more »

Investing Articles

The Lloyds share price could hit 80p in 2025!

The Lloyds share price could push as high as 80p in 2025, according to one highly respected analyst. Dr James…

Read more »

many happy international football fans watching tv
Investing Articles

This FTSE 250 stock offers no passive income but looks 42% undervalued to me!

Our writer has found one stock that he thinks could take off in 2025, even though it doesn’t offer the…

Read more »